Trial Profile
A study evaluating impact of baseline protease minority resistant variants on virological response to a protease inhibitor based regimens.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Nov 2017
Price :
$35
*
At a glance
- Drugs Atazanavir/ritonavir (Primary) ; Darunavir/ritonavir (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- 02 Nov 2017 New trial record
- 25 Oct 2017 Results published in the Journal of Antimicrobial Chemotherapy